Skip to main content

Nkarta, Inc.

NKTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001787400

No open-market purchases or sales by Nkarta, Inc. insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $167.9M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Nkarta, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of NKTX: Q2 2023 compared with Q3 2023
MeasureQ2 2023Of which not filed for Q3 2023Q3 2023Change
Holders97285−10
Shares39.5M83.8K36.5M−2.96M (−7.5%)
Value$86.5M$183.6K$50.7M−$35.7M (−41.3%)

2 institutions that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (11)

Institutions that held Nkarta, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to NKTX in Q3 2023
InstitutionSharesValue% of portfolio
Alyeska Investment Group, L.P.1,000,000$1.39M0.01%
Jefferies Financial Group Inc.250,000$347.5K0.01%
Monaco Asset Management SAM235,236$327.0K0.16%
Innovis Asset Management LLC138,962$193.2K0.07%
Acadian Asset Management LLC64,549$89.0K0.00%
State of Wyoming16,419$22.8K0.00%
Citadel Advisors LLC14,000$19.5K0.00%
JustInvest LLC11,613$16.1K0.00%
Qube Research & Technologies Ltd2,087$2.90K0.00%
Russell Investments Group, Ltd.996$1.38K0.00%
EverSource Wealth Advisors, LLC312$4340.00%

Sold out (21)

Institutions that held Nkarta, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Not filed for Q3 2023 yet (2)

Institutions that held Nkarta, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding NKTX in Q2 2023 that haven't filed for Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
BFT Financial Group, LLC54,848$120.1K
Tekla Capital Management LLC28,988$63.5K